About Multiple Sclerosis
Multiple sclerosis is a chronic, inflammatory medical condition, which results in demyelination, axonal transection, and neurodegeneration of the nerve cells of the brain and spinal cord. The immune system of the body targets the neurons within the CNS and damages the myelin sheath. It is a potentially debilitating disease, causing disruption in the communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with severe form of the disease can experience speech and movement problems. Multiple sclerosis can be broadly classified into four types: RRMS, SPMS, PPMS, and PRMS.
Technavio's analysts forecast the multiple sclerosis market in the US to grow at a CAGR of 3.8% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the multiple sclerosis market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of multiple sclerosis.
On the basis of route of administration of the drugs, the market is grouped into the following categories:
• Oral
• Parenteral
On the basis of type of molecule of the drugs, the market is grouped into the following categories:
• Small Molecules
• Biologics
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors and competitive performances of their product portfolios in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market.
Technavio's report, the multiple sclerosis market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the multiple sclerosis market in US market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Vendors
• Bayer AG
• Biogen
• Merck Serono
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
Other Prominent Vendors
• AB Science
• Abbvie
• Acorda Therapeutics
• Active Biotech
• Artielle
• Astellas
• AstraZeneca
• Canbex
• F. Hoffmann-La Roche
• GeNeuro
• GlaxoSmithKline
• Glenmark
• InnoBioscience Pharmaceuticals
• Ipsen
• Mapi-Pharma
• medDay Pharmaceuticals
• MediciNova
• Mitsubishi Tanabe
• Opexa Therapeutics
• Osmotica
• Pfizer
• Receptos
• RedHill Biopharma
• Sanofi
• Trophos
• XenoPort
Market Driver
• Unmet Medical Needs.
• For a full, detailed list, view our report.
Market Challenge
• Unknown Disease Etiology.
• For a full, detailed list, view our report.
Market Trend
• Introduction of Disease-modifying Drugs.
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 BetaseronExtavia
04.1.2 AvonexRebif
04.1.3 Tecfidera
04.1.4 Tysabri
04.1.5 Gilenya
04.1.6 Copaxone
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Multiple Sclerosis: An Overview
07.1.1 About the Disease
07.1.2 Signs and Symptoms
07.1.3 Etiology
07.1.4 Epidemiology
07.1.5 Economic Burden
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by Route of Administration
09.1 Multiple Sclerosis Market in US by Oral Drugs
09.1.1 Market Size and Forecast
09.2 Multiple Sclerosis Market in US by Parenteral Drugs
09.2.1 Market Size and Forecast
10. Market Segmentation by Type of Molecule
10.1 Multiple Sclerosis Market in US by Small Molecules
10.1.1 Market Size and Forecast
10.2 Multiple Sclerosis Market in US by Biologics
10.2.1 Market Size and Forecast
11. Pipeline Portfolio
11.1 Key Information of Late-stage Pipeline Molecules
11.1.1 Daclizumab High-yield Process (BIIB019)
11.1.2 RPC1063
11.1.3 Masitinib
11.1.4 Laquinimod
11.1.5 Natalizumab
11.1.6 Siponimod or BAF312
11.1.7 OS-440 (arbaclofen)
11.1.8 Ocrelizumab (RG1594)
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and Their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and Their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Competitive Landscape of Multiple Sclerosis Market in US
19.2.2 Biogen
19.2.3 Teva Pharmaceutical
19.2.4 Novartis
19.2.5 Merck Serono
19.2.6 Bayer
19.3 Other and Future Prominent Vendors
20. Key Vendor Analysis
20.1 Bayer
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Business Segmentation by Revenue 2014
20.1.4 Business Segmentation by Revenue 2013 and 2014
20.1.5 Geographical Segmentation by Revenue 2014
20.1.6 Business Strategy
20.1.7 Recent Developments
20.1.8 SWOT Analysis
20.2 Biogen
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Business Segmentation by Revenue 2013
20.2.4 Geographical Segmentation by Revenue 2013
20.2.5 Business Strategy
20.2.6 Key Developments
20.2.7 SWOT Analysis
20.3 Merck Serono
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Geographical Segmentation by Revenue 2013
20.3.4 Business Strategy
20.3.5 Recent Developments
20.3.6 SWOT Analysis
20.4 Novartis
20.4.1 Key Facts
20.4.2 Business Description
20.4.3 Business Segmentation
20.4.4 Revenue by Business Segmentation
20.4.5 Revenue Comparison 2012 and 2013
20.4.6 Sales by Geography
20.4.7 Business Strategy
20.4.8 Key Developments
20.4.9 SWOT Analysis
20.5 Teva Pharmaceutical
20.5.1 Key Facts
20.5.2 Business Overview
20.5.3 Business Segmentation
20.5.4 Revenue by Business Segmentation
20.5.5 Revenue Comparison 2012 and 2013
20.5.6 Revenue Segmentation by Geography
20.5.7 Business Strategy
20.5.8 Key Developments
20.5.9 SWOT Analysis
21. Other Reports in This Series
List Of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Frequency of Types of Multiple Sclerosis
Exhibit 3: Etiology of Multiple Sclerosis
Exhibit 4: Snapshot of Multiple Sclerosis Market in US
Exhibit 5: Multiple Sclerosis Market in US 2014-2019 ($ millions)
Exhibit 6: Segmentation of Multiple Sclerosis Market in US by Route of Administration
Exhibit 7: Segmentation of Multiple Sclerosis Market in US by Route of Administration 2014
Exhibit 8: Multiple Sclerosis Market in US by Oral Drugs 2014-2019 ($ millions)
Exhibit 9: Multiple Sclerosis Market in US by Parenteral Drugs 2014-2019 ($ millions)
Exhibit 10: Segmentation of Multiple Sclerosis Market in US by Route of Administration 2014 ($ millions)
Exhibit 11: Segmentation of Multiple Sclerosis Market in US by Type of Molecule
Exhibit 12: Segmentation of Multiple Sclerosis Market in US by Type of Molecule 2014
Exhibit 13: Multiple Sclerosis Market in US by Small Molecules 2014-2019 ($ millions)
Exhibit 14: Multiple Sclerosis Market in US by Biologics 2014-2019 ($ millions)
Exhibit 15: Segmentation of Multiple Sclerosis Market in US by Type of Molecule 2014 ($ millions)
Exhibit 16: Multiple Sclerosis Drugs Under Development
Exhibit 17: Multiple Sclerosis Drugs Under Various Developmental Phases
Exhibit 18: Major Drivers of Multiple Sclerosis Market in US
Exhibit 19: Major Challenges in Multiple Sclerosis Market in US
Exhibit 20: Major Trends in Multiple Sclerosis Market in US
Exhibit 21: Global Revenues of Top-selling Drugs for Multiple Sclerosis 2014 ($ millions)
Exhibit 22: YoY Global Growth of Top-selling Drugs for Multiple Sclerosis 2012-2014 ($ millions)
Exhibit 23: Biogen: YoY Global Revenue of Avonex 2011-2014 ($ millions)
Exhibit 24: Biogen: Revenue of Avonex in US 2011-2014 ($ millions)
Exhibit 25: Biogen: Revenue of Avonex in ROW 2011-2014 ($ millions)
Exhibit 26: Biogen: YoY Global Revenue of Tysabri 2011-2014 ($ millions)
Exhibit 27: Biogen: Revenue of Tysabri in US 2011-2014 ($ millions)
Exhibit 28: Biogen: Revenue of Tysabri in ROW 2011-2014 ($ millions)
Exhibit 29: Biogen: Revenue of Plegridy in US and ROW 2014 ($ millions)
Exhibit 30: Biogen: Revenue of Tecfidera in US and ROW 2014 ($ millions)
Exhibit 31: Teva Pharmaceutical: YoY Global Revenue of Copaxone 2011-2014 ($ millions)
Exhibit 32: Teva Pharmaceutical: Quarter-wise Revenue of Copaxone 2011-2014 ($ millions)
Exhibit 33: Novartis: YoY Global Revenue of Gilenya 2011-2014 ($ millions)
Exhibit 34: Novartis: Revenue of Gilenya in US and ROW 2011-2013 ($ millions)
Exhibit 35: Novartis: YoY Global Revenue of Extavia 2011-2014 ($ millions)
Exhibit 36: Merck Serono: YoY Global Revenue of Rebif 2011-2014 ($ millions)
Exhibit 37: Merck Serono: Revenue of Rebif in North America 2011-2014 ($ millions)
Exhibit 38: Merck Serono: Revenue of Rebif in Europe 2011-2014 ($ millions)
Exhibit 39: Merck Serono: Revenue Share of Rebif by Region 2012-2014
Exhibit 40: Bayer: YoY Global Revenue of Betaseron 2011-2014 ($ millions)
Exhibit 41: Bayer: Business Segmentation by Revenue 2014
Exhibit 42: Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 43: Bayer: Geographical Segmentation by Revenue 2014
Exhibit 44: Biogen: Business Segmentation by Revenue 2013
Exhibit 45: Biogen: Geographical Segmentation by Revenue 2013
Exhibit 46: Merck Serono: Geographical Segmentation by Revenue 2013
Exhibit 47: Novartis: Business Segmentation
Exhibit 48: Novartis: Revenue by Business Segmentation 2013
Exhibit 49: Novartis: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 50: Novartis: Revenue by Geographical Segmentation 2013
Exhibit 51: Teva Pharmaceutical: Business Segmentation
Exhibit 52: Teva Pharmaceutical: Revenue by Business Segmentation 2013
Exhibit 53: Teva Pharmaceutical: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 54: Teva Pharmaceutical: Revenue by Geographical Segmentation 2013
